Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe ClinicalTrials.gov record for a completed Phase 2 pancreatic cancer study is displayed, including its treatment arms, eligibility criteria, outcome measure, and study history.SummaryDifference40%

- Check14 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide NIH notice announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.1 to v3.7.2 on the error page.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check56 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the expected study details and navigation. This indicates the page is currently inaccessible due to access restrictions or server configuration.SummaryDifference17%

Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.